{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T01:50:14Z","timestamp":1789437014098,"version":"build-2803163510"},"reference-count":70,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T00:00:00Z","timestamp":1692921600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Hematological abnormalities are the most common early symptoms of Gaucher disease (GD), with an increased risk of hematopoietic system malignancies reported in patients with GD. GD may be associated with monoclonal and polyclonal gammopathies; however, the mechanism of association of GD with multiple myeloma (MM) remains uncertain. Enzyme replacement therapy (ERT) has been shown to improve patients\u2019 cytopenia and it seems to facilitate anti-myeloma therapy in patients with co-occurring GD and MM. Although it is necessary to demonstrate the deficiency of enzymatic activity, as well as using genetic tests to finally diagnose GD, due to changes in the blood count image, bone marrow biopsy is still a frequent element of the GD diagnosis procedure. The diagnosis of GD is often delayed, mainly due to the heterogeneity of the histopathological picture of bone marrow biopsy or overlapping hematological abnormalities. Unrecognized and untreated GD worsens the response of a patient with an oncological disease to targeted treatment. We present a literature review, inspired by the case of a Caucasian patient initially diagnosed with MM and later confirmed with comorbid GD type 1 (GD1). We would like to point out the problem of underdiagnosis and delay in patients with GD.<\/jats:p>","DOI":"10.3390\/jcm12175518","type":"journal-article","created":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T08:42:20Z","timestamp":1692952940000},"page":"5518","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Complexities of Diagnosis with Co-Existing Gaucher Disease and Hemato-Oncology\u2014A Case Report and Review of the Literature"],"prefix":"10.3390","volume":"12","author":[{"given":"Paulina","family":"Sudul","sequence":"first","affiliation":[{"name":"University Hospital, 30-688 Krakow, Poland"},{"name":"Unit of Rare Metabolic Diseases, Department of Metabolic Diseases, Jagiellonian University Medical College, 30-688 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata","family":"Piatkowska-Jakubas","sequence":"additional","affiliation":[{"name":"University Hospital, 30-688 Krakow, Poland"},{"name":"Department of Hematology, Jagiellonian University Medical College, 30-501 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukasz","family":"Pawlinski","sequence":"additional","affiliation":[{"name":"University Hospital, 30-688 Krakow, Poland"},{"name":"European Reference Network for Rare Metabolic Disease MetabERN, 30-688 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krystyna","family":"Galazka","sequence":"additional","affiliation":[{"name":"Department of Pathomorphology, Jagiellonian University Medical College, 31-531 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Sacha","sequence":"additional","affiliation":[{"name":"University Hospital, 30-688 Krakow, Poland"},{"name":"Department of Hematology, Jagiellonian University Medical College, 30-501 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2526-9714","authenticated-orcid":false,"given":"Beata","family":"Kiec-Wilk","sequence":"additional","affiliation":[{"name":"University Hospital, 30-688 Krakow, Poland"},{"name":"Unit of Rare Metabolic Diseases, Department of Metabolic Diseases, Jagiellonian University Medical College, 30-688 Krakow, Poland"},{"name":"European Reference Network for Rare Metabolic Disease MetabERN, 30-688 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,25]]},"reference":[{"key":"ref_1","unstructured":"Valle, D.L., Antonarakis, S., Ballabio, A., Beaudet, A.L., and Mitchell, G.A. (2019). The Online Metabolic and Molecular Bases of Inherited Disease, The McGraw-Hill Companies Hill, Inc.. Available online: https:\/\/ommbid.mhmedical.com\/content.aspx?bookid=2709&sectionid=225546386."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1080\/17474086.2021.1908120","article-title":"Hematological manifestations and complications of Gaucher disease","volume":"14","author":"Szer","year":"2021","journal-title":"Expert Rev. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s10545-008-0832-y","article-title":"\u2018Non-neuronopathic\u2019 Gaucher disease reconsidered. Prevalence of neurological manifestations in a Dutch cohort of type I Gaucher disease patients and a systematic review of the literature","volume":"31","author":"Biegstraaten","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ajhg.2011.03.005","article-title":"Insights into the pathogenesis and treatment of cancer from inborn errors of metabolism","volume":"88","author":"Erez","year":"2011","journal-title":"Am. J. Hum. Genet."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1081\/CNV-120002495","article-title":"The development of aggressive cancer: A possible role for sphingolipids","volume":"20","author":"Radin","year":"2002","journal-title":"Cancer Investig."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/j.1365-2141.2005.05503.x","article-title":"Evidence for a link between sphingolipid metabolism and expression of CD1d and MHC-class II: Monocytes from Gaucher disease patients as a model","volume":"129","author":"Balreira","year":"2005","journal-title":"Br. J. Haematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ymgme.2020.12.291","article-title":"Gaucher disease: Basic and translational science needs for more complete therapy and management","volume":"132","author":"Grabowski","year":"2021","journal-title":"Mol. Genet. Metab."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1615\/CritRevOncog.2013004503","article-title":"Immunological cells and functions in Gaucher disease","volume":"18","author":"Pandey","year":"2013","journal-title":"Crit. Rev. Oncog."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"790568","DOI":"10.3389\/fcell.2021.790568","article-title":"Alterations in Lysosome Homeostasis in Lipid-Related Disorders: Impact on Metabolic Tissues and Immune Cells","volume":"9","author":"Yuseff","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"bcr1120115087","DOI":"10.1136\/bcr-11-2011-5087","article-title":"Acute inflammatory neuropathy with monoclonal anti-GM2 IgM antibodies, IgM-\u03ba paraprotein and additional autoimmune processes in association with a diffuse large B-cell non-Hodgkin\u2019s lymphoma","volume":"2013","author":"Milnik","year":"2013","journal-title":"BMJ. Case Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ymgme.2020.12.295","article-title":"International Collaborative Gaucher Group (ICGG) Gaucher Registry (NCT00358943) investigators. Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain initial clinical improvements during twenty years of imiglucerase treatment","volume":"132","author":"Weinreb","year":"2021","journal-title":"Mol. Genet. Metab."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1615\/CritRevOncog.2013006061","article-title":"Gaucher disease and myeloma","volume":"18","author":"Ayto","year":"2013","journal-title":"Crit. Rev. Oncog."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.hemonc.2019.07.001","article-title":"Synchronous multiple myeloma and Gaucher disease","volume":"13","author":"Monge","year":"2020","journal-title":"Hematol. Oncol. Stem Cell Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-020-00359-2","article-title":"Multiple myeloma current treatment algorithms","volume":"10","author":"Rajkumar","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1182\/blood.V100.5.1817.h81702001817_1817_1827","article-title":"Generalized crystal-storing histiocytosis associated with monoclonal gammopathy: Molecular analysis of a disorder with rapid clinical course and review of the literature","volume":"100","author":"Lebeau","year":"2002","journal-title":"Blood"},{"key":"ref_16","first-page":"727","article-title":"Pseudo-Gaucher plasma cells in the bone marrow of a patient with monoclonal gammopathy of undetermined significance","volume":"82","author":"Regazzoli","year":"1997","journal-title":"Haematologica"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1365-2141.2007.06701.x","article-title":"Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease","volume":"138","author":"Hughes","year":"2007","journal-title":"Br. J. Haematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1186\/s13023-020-01544-z","article-title":"Patient reported outcome measures in a large cohort of patients with type 1 Gaucher disease","volume":"15","author":"Dinur","year":"2020","journal-title":"Orphanet. J. Rare Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1182\/blood-2004-12-4672","article-title":"Gaucher disease and cancer incidence: A study from the Gaucher Registry","volume":"105","author":"Rosenbloom","year":"2005","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/ajh.26675","article-title":"Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher Registry","volume":"97","author":"Rosenbloom","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.lungcan.2018.02.015","article-title":"Tumor associated macrophages support the growth of FGF9-induced lung adenocarcinoma by multiple mechanisms","volume":"119","author":"Hegab","year":"2018","journal-title":"Lung Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.15252\/embj.201797345","article-title":"Tumor-associated macrophages (TAMs) depend on ZEB1 for their cancer-promoting roles","volume":"36","author":"Darling","year":"2017","journal-title":"EMBO J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.bcmd.2016.10.018","article-title":"Gaucheromas: When macrophages promote tumor formation and dissemination","volume":"68","author":"Ivanova","year":"2018","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1615\/CritRevOncog.2013006145","article-title":"Gaucher disease and malignancy: A model for cancer pathogenesis in an inborn error of metabolism","volume":"18","author":"Mistry","year":"2013","journal-title":"Crit. Rev. Oncog."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"W\u0105tek, M., Piktel, E., Wollny, T., Durna\u015b, B., Fiedoruk, K., Lech-Mara\u0144da, E., and Bucki, R. (2019). Defective Sphingolipids Metabolism and Tumor Associated Macrophages as the Possible Links between Gaucher Disease and Blood Cancer Development. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20040843"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nrc3398","article-title":"Ceramide-orchestrated signalling in cancer cells","volume":"13","author":"Morad","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1182\/blood-2011-08-376236","article-title":"Dendritic cell-mediated activation-induced cytidine deaminase (AID)-dependent induction of genomic instability in human myeloma","volume":"119","author":"Koduru","year":"2012","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Dubot, P., Astudillo, L., Therville, N., Sabourdy, F., Stirnemann, J., Levade, T., and Andrieu-Abadie, N. (2020). Are Glucosylceramide-Related Sphingolipids Involved in the Increased Risk for Cancer in Gaucher Disease Patients? Review and Hypotheses. Cancers, 12.","DOI":"10.3390\/cancers12020475"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/acel.12409","article-title":"Lysosomal storage and impaired autophagy lead to inflammasome activation in Gaucher macrophages","volume":"15","author":"Aflaki","year":"2016","journal-title":"Aging Cell"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Pastores, G.M., and Hughes, D.A. (2017). Lysosomal Storage Disorders and Malignancy. Diseases, 5.","DOI":"10.3390\/diseases5010008"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/qjmed\/90.1.19","article-title":"Pro-inflammatory cytokines and the pathogenesis of Gaucher\u2019s disease: Increased release of interleukin-6 and interleukin-10","volume":"90","author":"Allen","year":"1997","journal-title":"QJM"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1309\/BG5VA8JRDQH1M7HN","article-title":"Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages","volume":"122","author":"Boven","year":"2004","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_33","first-page":"499","article-title":"Outcome of enzyme replacement therapy in Turkish patients with Gaucher disease: Does late intervention affect the response?","volume":"53","author":"Emre","year":"2011","journal-title":"Turk. J. Pediatr."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1097\/MEG.0b013e3283369f09","article-title":"Gaucher\u2019s disease type I: A disease masked by the presence of abnormal laboratory tests common to primary liver disease","volume":"22","author":"Saadi","year":"2010","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ymgme.2017.08.002","article-title":"Exploring the patient journey to diagnosis of Gaucher disease from the perspective of 212 patients with Gaucher disease and 16 Gaucher expert physicians","volume":"122","author":"Mehta","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/ajh.20908","article-title":"Consequences of diagnostic delays in type 1 Gaucher disease: The need for greater awareness among hematologists-oncologists and an opportunity for early diagnosis and intervention","volume":"82","author":"Mistry","year":"2007","journal-title":"Am. J. Hematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/jbmr.3734","article-title":"Gaucher disease in bone: From pathophysiology to practice","volume":"34","author":"Hughes","year":"2019","journal-title":"J. Bone Miner. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.bcmd.2003.10.007","article-title":"Effect of enzyme replacement therapy on gammopathies in Gaucher disease","volume":"32","author":"Brautbar","year":"2004","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1182\/asheducation-2005.1.340","article-title":"MGUS and smoldering multiple myeloma: Update on pathogenesis, natural history, and management","volume":"2005","author":"Rajkumar","year":"2005","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1172\/JCI0214530","article-title":"Systemic inflammation in glucocerebrosidase-deficient mice with minimal glucosylceramide storage","volume":"109","author":"Mizukami","year":"2002","journal-title":"J. Clin. Investig."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa1508808","article-title":"Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma","volume":"374","author":"Nair","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ymgme.2020.01.009","article-title":"Glucosylsphingosine but not Saposin C, is the target antigen in Gaucher disease-associated gammopathy","volume":"129","author":"Nair","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/bjh.15659","article-title":"Saposin C is a frequent target of paraproteins in Gaucher disease-associated MGUS\/multiple myeloma","volume":"184","author":"Preuss","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_44","unstructured":"(2023, May 08). Cancer Today International Agency for Research on Cancer World Health Organization. Available online: https:\/\/gco.iarc.fr\/today\/home."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ajh.21362","article-title":"The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients","volume":"84","author":"Taddei","year":"2009","journal-title":"Am. J. Hematol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"241","DOI":"10.5045\/br.2013.48.4.241","article-title":"Chronic myeloid leukemia with marked splenomegaly and pseudo-Gaucher cells","volume":"48","author":"Yang","year":"2013","journal-title":"Blood Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1136\/jcp.52.12.917","article-title":"Pseudo-Gaucher cells in myelodysplasia","volume":"52","author":"Stewart","year":"1999","journal-title":"J. Clin. Pathol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1532\/IJH97.06153","article-title":"Pseudo-Gaucher cell proliferation associated with myelodysplastic syndrome","volume":"85","author":"Saito","year":"2007","journal-title":"Int. J. Hematol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/ajcp\/87.4.533","article-title":"Pseudo-Gaucher cells in the bone marrow of a patient with Hodgkin\u2019s disease","volume":"87","author":"Zidar","year":"1987","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/10245330701393675","article-title":"Pseudo-Gaucher cells in Hb E disease and thalassemia intermedia","volume":"12","author":"Sharma","year":"2007","journal-title":"Hematology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/ajh.22269","article-title":"Pseudo-Gaucher cells in disseminated mycobacterial infection","volume":"88","author":"Busarla","year":"2013","journal-title":"Am. J. Hematol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Stirnemann, J., Belmatoug, N., Camou, F., Serratrice, C., Froissart, R., Caillaud, C., Levade, T., Astudillo, L., Serratrice, J., and Brassier, A. (2017). A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18020441"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"428","DOI":"10.4274\/tjh.2014.0019","article-title":"Gaucher Cells or Pseudo-Gaucher Cells: That\u2019s the Question","volume":"31","author":"Akay","year":"2014","journal-title":"Turk. J. Haematol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.bcmd.2005.08.004","article-title":"Increased incidence of cancer in adult Gaucher disease in Western Europe","volume":"36","author":"Weverling","year":"2006","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"62","DOI":"10.5603\/FHC.a2015.0003","article-title":"Atypical cytomorphology of Gaucher cells is frequently seen in bone marrow smears from untreated patients with Gaucher disease type 1","volume":"53","author":"Klimkowska","year":"2015","journal-title":"Folia Histochem. Cytobiol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.bcmd.2012.11.004","article-title":"Diagnosing Gaucher disease: An on-going need for increased awareness amongst haematologists","volume":"50","author":"Thomas","year":"2013","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1182\/blood.V76.3.646.646","article-title":"Misuse of marrow examination in the diagnosis of Gaucher disease","volume":"76","author":"Beutler","year":"1990","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Cazaubiel, T., Mulas, O., Montes, L., Schavgoulidze, A., Avet-Loiseau, H., Corre, J., and Perrot, A. (2020). Risk and Response-Adapted Treatment in Multiple Myeloma. Cancers, 12.","DOI":"10.3390\/cancers12123497"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1007\/s002770000202","article-title":"Coincidence of Gaucher\u2019s disease due to a 1226G\/1448C mutation and of an immunoglobulin G lambda multiple myeloma with Bence-Jones proteinuria","volume":"79","author":"Harder","year":"2000","journal-title":"Ann. Hematol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.2169\/internalmedicine.46.6243","article-title":"Type I Gaucher disease following chemotherapy for light chain multiple myeloma","volume":"46","author":"Cheung","year":"2007","journal-title":"Intern. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00277-008-0441-8","article-title":"Immunoglobulin and free light chain abnormalities in Gaucher disease type I: Data from an adult cohort of 63 patients and review of the literature","volume":"87","author":"Out","year":"2008","journal-title":"Ann. Hematol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/ajh.21492","article-title":"Treatment of multiple myeloma in patients with Gaucher disease","volume":"84","author":"Machaczka","year":"2009","journal-title":"Am. J. Hematol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s10545-018-0142-y","article-title":"Hepatocellular carcinoma in Gaucher disease: An international case series","volume":"41","author":"Regenboog","year":"2018","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/GIM.0b013e31818e2c19","article-title":"Dose-response relationships for enzyme replacement therapy with imiglucerase\/alglucerase in patients with Gaucher disease type 1","volume":"11","author":"Grabowski","year":"2009","journal-title":"Genet. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/ajmg.c.31870","article-title":"Outcomes of screening for gammopathies in children and adults with Gaucher disease type 1 in a cohort from Brazil and the United States","volume":"184","author":"Abell","year":"2020","journal-title":"Am. J. Med. Genet. C Semin. Med. Genet."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1182\/hematology.2020000123","article-title":"A patient with Gaucher disease and plasma cell dyscrasia: Bidirectional impact","volume":"2020","author":"Zimran","year":"2020","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/imj.15781","article-title":"Enzyme replacement therapy leading to improvement in myeloma indices in a patient with concomitant Gaucher disease","volume":"52","author":"Harel","year":"2022","journal-title":"Intern. Med. J."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/ajh.25300","article-title":"Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: Final results from the Phase 2 trial","volume":"94","author":"Lukina","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1002\/ajh.26276","article-title":"Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results","volume":"96","author":"Mistry","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/path.4452","article-title":"Inhibition of UDP-glucosylceramide synthase in mice prevents Gaucher disease-associated B-cell malignancy","volume":"235","author":"Pavlova","year":"2015","journal-title":"J. Pathol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/17\/5518\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:38:51Z","timestamp":1760128731000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/17\/5518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,25]]},"references-count":70,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["jcm12175518"],"URL":"https:\/\/doi.org\/10.3390\/jcm12175518","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,25]]}}}